$KOD

Kodiak Sciences (KOD) will announce topline results from its DAYBREAK Phase 3 study on Zenkuda and KSI-501 for wet age-related macular degeneration on September 28, 2026. The company will host a webcast to discuss the findings. Kodiak is a biotech firm focused on retinal therapies, with a market cap of $15 billion.

Kodiak Sciences (KOD) reported Q2 2026 results, highlighting three upcoming Phase 3 trial readouts by late 2026. The biotech's cash burn widened to $65.6M, with $125.9M in cash remaining. Trials focus on Zenkuda and KSI-501 for eye diseases, targeting a $15B market. Short interest is high at 25.94% of float.

Kodiak Sciences reported a Q2 2026 net loss of $65.6M, or $1.05 per share, for the quarter ended June 30, 2026, and cash and cash equivalents of $125.9M. R&D rose to $56.1M. The company reiterated Phase 3 readouts: DAYBREAK in Sept 2026 and PEAK Pivotal Analysis 1 in Dec 2026.

Kodiak Sciences Inc. (KOD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2026 Financial Results PALO ALTO, Calif., August 13, 2026 -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the second quarter ended June

Kodiak Sciences (Nasdaq: KOD) said it enrolled the first patients in its global Phase 3 ALTO trial of KSI-501 for diabetic macular edema. The study compares KSI-501 5 mg versus aflibercept 2 mg, aiming to show superiority and testing dosing intervals up to six months. About 910 patients are planned, with primary visual acuity endpoints at weeks 48-52.

Kodal Minerals (AIM: KOD) reported Bougouni lithium project results for the quarter ended 30 June 2026. Spodumene concentrate output was 26,174 DMT at 5.34% Li2O, with 53,195 DMT year to date. A US$13m initial repayment was made by operator LMLB to KMUK. Third shipment (~20,400 DMT) arrived in Hainan; interim payment was $34.4m for 95% of estimated value.

MarketBeat reports that eight brokerages covering Kodiak Sciences (NASDAQ:KOD) give an average “Moderate Buy” rating, with one sell, one hold, and six buy ratings. The average 1-year price target is $42.14. UBS raised its target to $80; HC Wainwright set $58; Chardan lifted to $61. KOD shares opened at $32.94 and last reported EPS of ($0.94) for May 7, slightly below consensus.

Kodiak Sciences CFO John A. Borgeson sold 30,000 shares on June 4, 2026 via option exercise and immediate open-market sale, according to an SEC Form 4. The weighted average purchase price was $34.10. His direct holdings fell 12.40% to 211,930 shares, leaving about $7.24 million in direct common stock value. The sale followed a 10b5-1 plan.

BORGESON JOHN A. (Chief Financial Officer) sold 4,104 shares of Kodiak Sciences Inc. (KOD) at $34.67 ($0.14M total) on 2026-06-04 under a Rule 10b5-1 trading plan.

BORGESON JOHN A. (Chief Financial Officer) sold 25,896 shares of Kodiak Sciences Inc. (KOD) at $34.01 ($0.88M total) on 2026-06-04 under a Rule 10b5-1 trading plan.